Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vyxeos + clofarabine dose-finding study in children with relapsed/refractory AML
NL-OMON55064Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jan 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine and clofarabine in acute myeloid leukemia (AML), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Dose-limiting toxicities during course 1. Started Jan 2022; status: recruiting.
02
Drugs
cytarabineclofarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON55064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55064.